Sunmax Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
May 13, 2021
Share
Sunmax Biotechnology Co., Ltd. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced total revenue was TWD 267.047 million compared to TWD 170.890 million a year ago. Operating income was TWD 90.425 million compared to TWD 96.531 million a year ago. Net income was TWD 62.935 million compared to TWD 56.302 million a year ago. Basic earnings per share from continuing operations was TWD 1.16 compared to TWD 1.03 a year ago. Diluted earnings per share from continuing operations was TWD 1.15 compared to TWD 1.03 a year ago.
SunMax Biotechnology Co., Ltd. is a Taiwan-based company principally engaged in research, development, production and distribution of collagen implants and related products. The Company's major products include collagen, collagen implants, microfiber collagen hemostat, collagen absorbable hemostat pads, healthcare products, as well as medical collagen application equipment. Its products are applied in medical and beauty care industrials. The Company distributes its products principally in Taiwan, Mainland China and other regions.